BCYC
Bicycle Therapeutics LtdNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$317.64M
P/E Ratio
—
EPS
$-3.15
Beta
1.65
52W High
$9.36
52W Low
$4.24
50-Day MA
$4.78
200-Day MA
$6.37
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Bicycle Therapeutics Ltd
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, is developing a class of drugs for diseases that are not served by existing treatments. The company is headquartered in Cambridge, the United Kingdom.
Fundamentals
| Revenue (TTM) | $72.59M |
| Gross Profit (TTM) | $-156.50M |
| EBITDA | $-236.44M |
| Operating Margin | -42.80% |
| Return on Equity | -31.20% |
| Return on Assets | -18.10% |
| Revenue/Share (TTM) | $1.05 |
| Book Value | $8.79 |
| Price-to-Book | 0.57 |
| Price-to-Sales (TTM) | 4.38 |
| EV/Revenue | 21.22 |
| EV/EBITDA | -2.14 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 1193.00% |
| Shares Outstanding | $50.37M |
| Float | $1.88M |
| % Insiders | 4.42% |
| % Institutions | 73.18% |
Historical Volatility
HV 10-Day
33.59%
HV 20-Day
38.76%
HV 30-Day
43.17%
HV 60-Day
50.87%
HV Rank
13.9%
Volatility is currently contracting
Analyst Ratings
Consensus ($12.11 target)
2
Strong Buy5
Buy4
HoldMore HEALTHCARE Stocks
Data last updated: 5/25/2026